Form 6-K Ascendis Pharma A/S For: Sep 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
September 5, 2024 6:54 AM EDTOppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.
The analyst comments "We upgrade ASND to Outperform (from Perform) and assign a $180 PT ahead of 1) Yorvipath's US launch for hypoparathyroidism (to commence by 1Q25)... More
Ascendis Pharma (ASND) PT Lowered to $174 at Jefferies
September 4, 2024 5:18 AM EDTJefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $174.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Skytrofa experienced a revenue growth reversal in Q2 (26M; -58% Q/Q; -25% YoY) on an unexpected net price... More
Ascendis Pharma (ASND) PT Lowered to $180 at Goldman Sachs
September 4, 2024 5:06 AM EDTGoldman Sachs analyst Paul Choi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "Miss for Skytrofa on the back of insurance contract resets and significant price pressure; focus remains on upcoming US... More
Ascendis Pharma (ASND) PT Lowered to $178 at Citi
September 4, 2024 4:57 AM EDTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $193.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 2Q24 financial results, missing Street estimates on topline revenue and GAAP EPS as the company made significant accounting... More
